These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35641285)

  • 1. Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: Outcomes and Survival From an Australian Centre.
    Shamavonian R; Cheng E; Karpes JB; Barat S; Ahmadi N; Morris DL
    Anticancer Res; 2022 Jun; 42(6):2939-2944. PubMed ID: 35641285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
    Valenzuela CD; Solsky IB; Erali RA; Forsythe SD; Mangieri CW; Mainali BB; Russell G; Perry KC; Votanopoulos KI; Shen P; Levine EA
    Ann Surg Oncol; 2023 May; 30(5):2666-2675. PubMed ID: 36754945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 4. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.
    Aydin N; Sardi A; Milovanov V; Nieroda C; Sittig M; Nunez MF; Jimenez W; Gushchin V
    Am Surg; 2015 Dec; 81(12):1253-9. PubMed ID: 26736164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
    Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
    J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?
    Mollaoğlu MC; Karabacak U; Bostancı ME; Seven TE; Karadayı K
    Acta Chir Belg; 2024 Aug; 124(4):281-289. PubMed ID: 38294331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis.
    Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC
    ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
    Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
    Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
    Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
    Huang Y; Alzahrani NA; Liauw W; Morris DL
    Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    Calthorpe L; Romero-Hernandez F; Casey M; Nunez M; Conroy PC; Hirose K; Kim A; Kirkwood K; Maker AV; Corvera C; Nakakura E; Alseidi A; Adam MA
    Ann Surg Oncol; 2023 Aug; 30(8):5119-5129. PubMed ID: 37140748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.